Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favors M1 macrophage development.

Stalder R, Zhang B, Jean Wrobel L, Boehncke WH, Brembilla NC.

Exp Dermatol. 2019 Nov 12. doi: 10.1111/exd.14059. [Epub ahead of print]

PMID:
31721311
2.

Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry.

Cazzaniga S, Anzengruber F, Augustin M, Boehncke WH, Borradori L, Conrad C, Cozzio A, Djamei V, French LE, Gilliet M, Häusermann P, Heidemeyer K, Itin P, Kolios AGA, Laffitte E, Maul JT, Mainetti C, Naldi L, Navarini AA, Rustenbach SJ, Simon D, Sorbe C, Streit M, Yawalkar N.

J Eur Acad Dermatol Venereol. 2019 Sep 28. doi: 10.1111/jdv.15983. [Epub ahead of print]

PMID:
31562785
3.

Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line.

Vorobyev A, Gupta Y, Sezin T, Koga H, Bartsch YC, Belheouane M, Künzel S, Sina C, Schilf P, Körber-Ahrens H, Beltsiou F, Lara Ernst A, Khil'chenko S, Al-Aasam H, Manz RA, Diehl S, Steinhaus M, Jascholt J, Kouki P, Boehncke WH, Mayadas TN, Zillikens D, Sadik CD, Nishi H, Ehlers M, Möller S, Bieber K, Baines JF, Ibrahim SM, Ludwig RJ.

Nat Commun. 2019 Sep 10;10(1):4097. doi: 10.1038/s41467-019-11952-w.

4.

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase 2 Trial.

Helliwell PS, Deodhar A, Gottlieb AB, Boehncke WH, Xu XL, Xu S, Wang Y, Hsia EC, Gladman DD, Ritchlin CT.

Arthritis Care Res (Hoboken). 2019 Aug 17. doi: 10.1002/acr.24046. [Epub ahead of print]

PMID:
31421033
5.

Autoreactive T-Lymphocytes in Inflammatory Skin Diseases.

Boehncke WH, Brembilla NC.

Front Immunol. 2019 May 29;10:1198. doi: 10.3389/fimmu.2019.01198. eCollection 2019. Review.

6.

Best-practice Indicators in Psoriatic Disease Care.

Helliwell PS, Favier G, Gladman DD, Soriano ER, Kirkham BW, Coates LC, Puig L, Boehncke WH, Thaçi D.

J Rheumatol Suppl. 2019 Jun;95:38-45. doi: 10.3899/jrheum.190120.

PMID:
31154403
7.

Cardiovascular Diseases in Psoriasis and Psoriatic Arthritis.

Eder L, Dey A, Joshi AA, Boehncke WH, Mehta NN, Szentpetery A.

J Rheumatol Suppl. 2019 Jun;95:20-27. doi: 10.3899/jrheum.190114.

PMID:
31154400
8.

GRAPPA Trainees Symposium 2018: A Report from the GRAPPA 2018 Annual Meeting.

Ford AR, Mascia E, Boehncke WH, Ritchlin CT.

J Rheumatol Suppl. 2019 Jun;95:4-10. doi: 10.3899/jrheum.190123.

PMID:
31154398
9.

[A case of « peau d'orange » in the absence of cancer].

Boehncke WH, Zürcher S, Kaya G.

Rev Med Suisse. 2019 Mar 27;15(644):685-686. French.

PMID:
30916907
10.

Cave linguam – ce qu’on dit (ou écrit) et ce que le public entend….

Boehncke WH.

Rev Med Suisse. 2019 Mar 27;15(644):659-660. French. No abstract available.

PMID:
30916902
11.

IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation.

Senra L, Mylonas A, Kavanagh RD, Fallon PG, Conrad C, Borowczyk-Michalowska J, Wrobel LJ, Kaya G, Yawalkar N, Boehncke WH, Brembilla NC.

J Invest Dermatol. 2019 Aug;139(8):1732-1742.e17. doi: 10.1016/j.jid.2019.01.021. Epub 2019 Feb 6.

PMID:
30738055
12.

Regulatory cells in the skin: Pathophysiologic role and potential targets for anti-inflammatory therapies.

Uttarkar S, Brembilla NC, Boehncke WH.

J Allergy Clin Immunol. 2019 Apr;143(4):1302-1310. doi: 10.1016/j.jaci.2018.12.1011. Epub 2019 Jan 18.

PMID:
30664891
13.

Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial.

Kromer C, Nühnen VP, Pfützner W, Pfeiffer S, Laubach HJ, Boehncke WH, Liebmann J, Born M, Schön MP, Buhl T.

JMIR Res Protoc. 2019 Jan 8;8(1):e11911. doi: 10.2196/11911.

14.

Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients.

Augustin M, Sommer R, Kirsten N, Danckworth A, Radtke MA, Reich K, Thaci D, Boehncke WH, Langenbruch A, Mrowietz U.

Br J Dermatol. 2019 Aug;181(2):358-365. doi: 10.1111/bjd.17403. Epub 2019 Jan 24.

PMID:
30430557
15.

Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice.

Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, Drach M, Blome C, Boehncke WH, Thaci D, Reich K, von Kiedrowski R, Körber A, Yawalkar N, Mainetti C, Laffitte E, Streit M, Rustenbach S, Conrad C, Borradori L, Gilliet M, Cozzio A, Itin P, Häusermann P, French LE, Radtke MA, Augustin M.

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):700-708. doi: 10.1111/jdv.15324. Epub 2019 Jan 15.

PMID:
30388318
16.

Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus.

Mrowietz U, Barker J, Boehncke WH, Iversen L, Kirby B, Naldi L, Reich K, Tanew A, van de Kerkhof PCM, Warren RB.

J Eur Acad Dermatol Venereol. 2018 Oct;32 Suppl 3:3-14. doi: 10.1111/jdv.15218. Epub 2018 Sep 20.

PMID:
30238510
17.

The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond.

Brembilla NC, Senra L, Boehncke WH.

Front Immunol. 2018 Aug 2;9:1682. doi: 10.3389/fimmu.2018.01682. eCollection 2018. Review.

18.

Roger federer pourrait-il jouer en portant un large sombrero ?

Merat R, Gilliet M, Boehncke WH, Gaide O.

Rev Med Suisse. 2018 Aug 8;14(614):1422-1423. French. No abstract available.

PMID:
30091335
19.

Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study.

de Vlam K, Merola JF, Birt JA, Sandoval DM, Lobosco S, Moon R, Milligan G, Boehncke WH.

Rheumatol Ther. 2018 Dec;5(2):423-436. doi: 10.1007/s40744-018-0120-8. Epub 2018 Jul 6.

20.

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.

Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, Barchuk W, Xu XL, Hsia EC; CNTO1959PSA2001 Study Group.

Lancet. 2018 Jun 2;391(10136):2213-2224. doi: 10.1016/S0140-6736(18)30952-8. Epub 2018 Jun 1.

PMID:
29893222
21.

S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations.

Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Härle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T.

J Dtsch Dermatol Ges. 2018 Jun;16(6):806-813. doi: 10.1111/ddg.13538.

PMID:
29873906
22.

S3-Leitlinie zur Therapie der Psoriasis vulgaris Update - Kurzfassung Teil 2 - Besondere Patientengruppen und spezielle Behandlungssituationen.

Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Härle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T.

J Dtsch Dermatol Ges. 2018 Jun;16(6):806-814. doi: 10.1111/ddg.13538_g.

PMID:
29873903
23.

GRAPPA Trainees Symposium 2017: A Report from the GRAPPA 2017 Annual Meeting.

Furer V, Manasson J, Boehncke WH, Ritchlin CT.

J Rheumatol Suppl. 2018 Jun;94:4-10. doi: 10.3899/jrheum.180130.

PMID:
29858346
24.

S3-Leitlinie zur Therapie der Psoriasis vulgaris Update - Kurzfassung Teil 1 - Systemische Therapie.

Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Härle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T.

J Dtsch Dermatol Ges. 2018 May;16(5):645-670. doi: 10.1111/ddg.13516_g. No abstract available.

PMID:
29750455
25.

S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment.

Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Härle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T.

J Dtsch Dermatol Ges. 2018 May;16(5):645-669. doi: 10.1111/ddg.13516.

PMID:
29750443
26.

Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey.

Armstrong A, Jarvis S, Boehncke WH, Rajagopalan M, Fernández-Peñas P, Romiti R, Bewley A, Vaid B, Huneault L, Fox T, Sodha M, Warren RB.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2200-2207. doi: 10.1111/jdv.15065. Epub 2018 Jul 31.

PMID:
29730888
27.

Immunogenicity of biologic therapies: causes and consequences.

Boehncke WH, Brembilla NC.

Expert Rev Clin Immunol. 2018 Jun;14(6):513-523. doi: 10.1080/1744666X.2018.1468753. Epub 2018 Apr 25. Review.

PMID:
29683362
28.

Low incidence of heparin-induced skin lesions in orthopedic surgery patients with low-molecular-weight heparins.

Schindewolf M, Paulik M, Kroll H, Kaufmann R, Wolter M, Boehncke WH, Lindhoff-Last E, Recke A, Ludwig RJ.

Clin Exp Allergy. 2018 Aug;48(8):1016-1024. doi: 10.1111/cea.13159. Epub 2018 Jun 5.

PMID:
29683226
29.

Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences.

Boehncke WH.

Front Immunol. 2018 Apr 5;9:579. doi: 10.3389/fimmu.2018.00579. eCollection 2018. Review.

30.

Recognition of early melanoma: a monocentric dermoscopy follow-up study comparing de novo melanoma with nevus-associated melanoma.

Alvarez Martinez D, Boehncke WH, Kaya G, Merat R.

Int J Dermatol. 2018 Jun;57(6):692-702. doi: 10.1111/ijd.13977. Epub 2018 Apr 2. Erratum in: Int J Dermatol. 2018 Aug;57(8):1017.

PMID:
29611194
31.

[Repurposing of betablockers in dermatology].

Wrobel LJ, Boehncke WH, Le Gal FA.

Rev Med Suisse. 2018 Mar 28;14(600):670-675. French.

PMID:
29589653
32.

Innovation en dermatologie : il est temps de changer de mentalité !

Gilliet M, Boehncke WH.

Rev Med Suisse. 2018 Mar 28;14(600):659-660. French. No abstract available.

PMID:
29589651
33.

Who will treat inflammatory skin diseases in the year 2020?

Boehncke WH.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):e435-e436. doi: 10.1111/jdv.14954. Epub 2018 Apr 10. No abstract available.

PMID:
29575273
34.

[Fumarates - far more than a dietary supplement].

Boehncke WH, Brembilla NC.

Rev Med Suisse. 2018 Jan 10;14(588-589):27-29. French.

PMID:
29337444
35.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.

36.

New biologics in psoriasis - progress and problems.

Boehncke WH.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1577-1578. doi: 10.1111/jdv.14576. No abstract available.

PMID:
29059511
37.

Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment.

Boehncke WH, Brembilla NC.

Clin Rev Allergy Immunol. 2018 Dec;55(3):295-311. doi: 10.1007/s12016-017-8634-3. Review.

PMID:
28780731
38.

[Nail changes : diagnostic considerations in everyday medical general practice].

De Lorenzi C, Abosaleh M, Boehncke WH.

Rev Med Suisse. 2017 Mar 29;13(556):691-696. French.

PMID:
28722379
39.

Choisir le bon médicament pour votre patient : evidence vs eminence-based medicine.

Boehncke WH, Gilliet M.

Rev Med Suisse. 2017 Mar 29;13(556):675-676. French. No abstract available.

PMID:
28722376
40.

[The dermatological indications of laser: beyond cosmetic target.]

Abosaleh M, Boehncke WH, Laubach H.

Rev Med Suisse. 2017 Jan 11;13(544-545):37-39. Review. French.

PMID:
28703533
41.

Inflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation.

Buerger C, Shirsath N, Lang V, Berard A, Diehl S, Kaufmann R, Boehncke WH, Wolf P.

PLoS One. 2017 Jul 10;12(7):e0180853. doi: 10.1371/journal.pone.0180853. eCollection 2017.

42.

The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis.

Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke WH, Prinz JC.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1616-1626. doi: 10.1111/jdv.14433. Epub 2017 Aug 29. Review.

43.

Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition.

Fernandez M, Sutterlüty-Fall H, Schwärzler C, Lemeille S, Boehncke WH, Merat R.

Cancer Med. 2017 Jul;6(7):1652-1664. doi: 10.1002/cam4.1091. Epub 2017 Jun 1.

44.
45.

Benchmarking Care in Psoriatic Arthritis - The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting.

Favier G, Gladman DD, Merola JF, Armstrong AW, Boehncke WH, Helliwell PS.

J Rheumatol. 2017 May;44(5):674-678. doi: 10.3899/jrheum.170142.

PMID:
28461523
46.

"Evergreen" Psoriasis - Neues zu Genetik, Therapie, und überhaupt.

Boehncke WH.

J Dtsch Dermatol Ges. 2017 Feb;15(2):111-112. doi: 10.1111/ddg.13175. No abstract available.

PMID:
28214311
47.

IL-17A localizes in the exocytic compartment of mast cells in psoriatic skin.

Brembilla NC, Stalder R, Senra L, Boehncke WH.

Br J Dermatol. 2017 Nov;177(5):1458-1460. doi: 10.1111/bjd.15358. Epub 2017 Aug 16. No abstract available.

PMID:
28144966
48.

Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry.

Jungo P, Maul JT, Djamei V, von Felten S, Kolios AGA, Czernielewsk J, Yawalkar N, Odermatt O, Laffitte E, Anliker M, Streit M, Augustin M, Conrad C, Hafner J, Boehncke WH, Gilliet M, Itin P, French LE, Navarini AA, Häusermann P.

Dermatology. 2016;232(6):655-663. doi: 10.1159/000455042. Epub 2017 Jan 20.

49.

Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.

Maul JT, Djamei V, Kolios AGA, Meier B, Czernielewski J, Jungo P, Yawalkar N, Mainetti C, Laffitte E, Spehr C, Anliker M, Streit M, Augustin M, Rustenbach S, Conrad C, Hafner J, Boehncke WH, Borradori L, Gilliet M, Itin P, French LE, Häusermann P, Navarini AA.

Dermatology. 2016;232(6):640-647. doi: 10.1159/000452740. Epub 2017 Jan 12.

50.

Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis.

Senra L, Stalder R, Alvarez Martinez D, Chizzolini C, Boehncke WH, Brembilla NC.

J Invest Dermatol. 2016 Oct;136(10):1970-1980. doi: 10.1016/j.jid.2016.06.009. Epub 2016 Jun 18.

Supplemental Content

Loading ...
Support Center